MEN1/DAXX/ATRX mutations enhance progression-free survival in gastroenteropancreatic neuroendocrine tumors treated with peptide receptor radionuclide therapy
Endocrine-Related Cancer · 2024
DOI: 10.1530/erc-24-0065 ↗Kurz gefasst
Fachartikel in der Zeitschrift Endocrine-Related Cancer, 2024. Verfasst von Rushabh Gujarathi und 8 weiteren Autor:innen. Beteiligte Einrichtung: Section of Hematology and Oncology, Department of Medicine, University of Chicago, Chicago, Illinois, USA. Hauptthemen laut MEDLINE: Neuroendocrine Tumors, Pancreatic Neoplasms, Co-Repressor Proteins, Intestinal Neoplasms. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 38 Literaturangaben.
Abstract (Originalsprache)
Pre-clinical data suggest that mutations in the MEN1 , DAXX , and/or ATRX genes may potentially increase radiation efficacy in cancer cells. Herein, we explore the association between response to peptide receptor radionuclide therapy (PRRT) and those mutations in patients with gastroenteropancreatic neuroendocrine tumors (GEP-NETs). We analyzed tissue-based next generation sequencing (NGS) assay results and clinicopathologic data from 28 patients with GEP-NETs treated with PRRT. Findings were correlated with progression-free survival (PFS) and objective response rate (ORR). Patients with mutations in MEN1 , DAXX , and/or ATRX ( n = 13) had a longer median PFS (26.47 vs 12.13 months; P = 0.014) than wild-type ( n = 15) patients when adjusted for surgery prior to PRRT, tumor grade, and presence of TP53 mutation. Alterations in MEN1 along with a concurrent mutation in either DAXX or ATRX ( n = 6) trended toward longer PFS compared to patients without concurrent mutations (31.53 vs 17.97 months; P = 0.09). ORR was higher in patients with a mutation in MEN1 , DAXX , or ATRX (41.67% vs 15.38%). In pancreatic NET patients, these target mutations also showed a longer PFS (28.43 vs 9.83 months; P = 0.04). TP53 alterations showed a shorter PFS than wild-type cases (11.17 vs 20.47 months; P = 0.009). Mutations in MEN1 / DAXX / ATRX are associated with improved PFS in patients with GEP-NETs receiving PRRT and might be used as a biomarker for treatment response.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Section of Hematology and Oncology, Department of Medicine, University of Chicago, Chicago, Illinois, USA.
- Section of Endocrine Surgery, Department of Surgery, University of Chicago, Chicago, Illinois, USA.
- Department of Pathology, University of Chicago, Chicago, Illinois, USA.
- Department of Radiology, University of Chicago, Chicago, Illinois, USA.
ORCID-Profile: Rushabh Gujarathi, Chih-Yi Liao
Zitieren
APA
Gujarathi, R., Abou Azar, S., Tobias, J., Polite, B. N., Setia, N., Feinberg, N., Appelbaum, D. E., Keutgen, X. M., & Liao, C. Y. (2024). MEN1/DAXX/ATRX mutations enhance progression-free survival in gastroenteropancreatic neuroendocrine tumors treated with peptide receptor radionuclide therapy. Endocrine-Related Cancer. https://doi.org/10.1530/erc-24-0065
Vancouver
Gujarathi R, Abou Azar S, Tobias J, Polite BN, Setia N, Feinberg N, et al. MEN1/DAXX/ATRX mutations enhance progression-free survival in gastroenteropancreatic neuroendocrine tumors treated with peptide receptor radionuclide therapy. Endocrine-Related Cancer. 2024. doi:10.1530/erc-24-0065
BibTeX
@article{Gujarathi2024,
author = {Gujarathi, Rushabh and Abou Azar, Sara and Tobias, Joseph and Polite, Blase N and Setia, Namrata and Feinberg, Nicholas and Appelbaum, Daniel E and Keutgen, Xavier M and Liao, Chih-Yi},
title = {MEN1/DAXX/ATRX mutations enhance progression-free survival in gastroenteropancreatic neuroendocrine tumors treated with peptide receptor radionuclide therapy},
journal = {Endocrine-Related Cancer},
year = {2024},
doi = {10.1530/erc-24-0065}
}
EUVIMED